Arcturus Therapeutics
ARCT
45 hedge funds and large institutions have $91.2M invested in Arcturus Therapeutics in 2016 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 7 closing their positions.
266% more call options, than puts
Call options by funds: $2.96M | Put options by funds: $808K
60% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 10
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
15% more capital invested
Capital invested by funds: $79M → $91.2M (+$12.1M)
2% less funds holding
Funds holding: 46 → 45 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VMI
VHCP Management II
New York
|
+$1.46M |
| 2 |
VM
VHCP Management
New York
|
+$625K |
| 3 |
JG
Jefferies Group
New York
|
+$535K |
| 4 |
LCM
Leisure Capital Management
Costa Mesa,
California
|
+$108K |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$83.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.73M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.12M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$822K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$238K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$94K |
ARCT Hedge Fund Activity: Q2 2016 in Review
45 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q2 2016, worth a combined $91.2M — up 15% from $79M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ARCT and 6 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 16 added.
The largest buyer was VHCP Management II, adding an estimated $1.46M. The largest seller was Great Point Partners, cutting an estimated $2.73M.
- 45 institutional investors held Arcturus Therapeutics (ARCT) as of Q2 2016, down from 46 in Q1 2016.
- Funds reported $91.2M of Arcturus Therapeutics stock for Q2 2016, up 15% quarter-over-quarter.
- 6 funds opened new Arcturus Therapeutics positions in Q2 2016 and 7 closed out, a net change of -1 holder.
- The largest Arcturus Therapeutics buyer in Q2 2016 was VHCP Management II, an estimated $1.46M added.
- The largest Arcturus Therapeutics seller in Q2 2016 was Great Point Partners, an estimated $2.73M sold.
Based on aggregated 13F filings for Q2 2016.